



## RESEARCH ARTICLE

**REVISED** **Impact of *Plasmodium falciparum* small-sized extracellular vesicles on host peripheral blood mononuclear cells [version 2; peer review: 1 approved, 2 not approved]**

Shaban J. Mwangi <sup>1,2</sup>, Agnes Gwela<sup>1</sup>, Kioko Mwikali<sup>1</sup>, Joel L. Bargul<sup>2,3</sup>, Eunice W. Nduati <sup>1</sup>, Francis M. Ndungu <sup>1</sup>, Philip Bejon <sup>1</sup>, Julian C. Rayner <sup>4</sup>, Abdirahman I. Abdi <sup>1,5</sup>

<sup>1</sup>Bioscience Department, KEMRI-Wellcome Trust, CGMRC, Kilifi, 80108, Kenya

<sup>2</sup>Biochemistry Department, Jomo Kenyatta University of Agriculture and Technology, P.O. Box, 62000-00200, Nairobi, Kenya

<sup>3</sup>International Centre of Insect Physiology and Ecology, Nairobi, 00100, Kenya

<sup>4</sup>Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK

<sup>5</sup>Pwani University Biosciences Research Centre, Pwani University, KILIFI, 80108, Kenya

**v2** First published: 21 Aug 2020, 5:197  
<https://doi.org/10.12688/wellcomeopenres.16131.1>

Latest published: 13 Apr 2021, 5:197  
<https://doi.org/10.12688/wellcomeopenres.16131.2>

### Abstract

**Background:** Exaggerated immune activation has a key role in the pathogenesis of malaria. During blood-stage infection, *Plasmodium falciparum* can interact directly with host immune cells through infected red blood cells (*PfiRBCs*), or indirectly by the release of extracellular vesicles (EVs). Here, we compared the impact of *PfiRBCs* and *P. falciparum* small-sized EVs (*PfsEVs*, also known as exosomes) from a Kenyan clinical isolate (*PfKE12*) adapted to short-term laboratory culture conditions on host peripheral blood mononuclear cells (PBMC).

**Methods:** *PfsEVs* were isolated from cell-free culture-conditioned media by ultracentrifugation while mature trophozoite *PfiRBCs* were purified by magnetic column separation. The *PfsEVs* and the *PfiRBCs* were co-cultured for 18 hours with PBMC. Cellular responses were quantified by cell surface expression of activation markers (CD25, CD69) and cytokine/chemokine levels in the supernatant.

**Results:** Relative to negative control conditions, *PfsEVs* induced CD25 expression on CD4<sup>+</sup>, CD19<sup>+</sup> and CD14<sup>+</sup> cells, while *PfiRBCs* induced on CD19<sup>+</sup> and CD14<sup>+</sup> cells. Both *PfsEVs* and *PfiRBCs* induced CD69 on CD4<sup>+</sup>, CD8<sup>+</sup> and CD19<sup>+</sup> cells. In addition, *PfiRBCs* induced higher expression of CD69 on CD14<sup>+</sup> cells. CD69 induced by *PfiRBCs* on CD4<sup>+</sup> and CD19<sup>+</sup> cells was significantly higher than that induced by *PfsEVs*. Secretion of MIP1 $\alpha$ , MIP1 $\beta$ , GM-CSF, IL-6, IL-8, and TNF $\alpha$  were significantly induced by both *PfsEVs* and *PfiRBCs* whereas MCP-1, IL-10, IL-17 $\alpha$  were preferentially induced by *PfsEVs* and IP-10 and IFN- $\gamma$  by *PfiRBCs*. Prior exposure to malaria (judged by antibodies to

### Open Peer Review

Reviewer Status

	Invited Reviewers		
	1	2	3
<b>version 2</b> (revision) 13 Apr 2021		report	
<b>version 1</b> 21 Aug 2020	report	report	report

1. **Smart Ikechukwu Mbagwu** , University of Fribourg, Fribourg, Germany
2. **Carmenza Spadafora** , Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), City of Knowledge, Apartado, Panama, Panama  
**Ricardo Correa**, International Centre of Biotechnology and Genetic Engineering (ICGEB), Trieste, Italy
3. **Valery Combes**, University Technology of

schizont extract) was associated with lower monocyte responses to *Pf*sEVs.

**Conclusions:** *Pf*sEVs and *Pf*iRBCs showed differential abilities to induce secretion of IL-17 $\alpha$  and IFN- $\gamma$ , suggesting that the former are better at inducing Th17, whilst the latter induce Th1 immune responses respectively. Prior exposure to malaria significantly reduces the ability of *Pf*sEVs to activate monocytes, suggesting immune tolerance to *Pf*sEVs may play a role in naturally acquired anti-disease immunity.

### Keywords

Malaria, Plasmodium falciparum, small extracellular vesicles, PBMC, immune response

Sydney, Sydney, Australia

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the [KEMRI | Wellcome Trust gateway](#).

**Corresponding author:** Abdirahman I. Abdi ([aabdi@kemri-wellcome.org](mailto:aabdi@kemri-wellcome.org))

**Author roles:** **Mwangi SJ:** Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Gwela A:** Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Writing – Review & Editing; **Mwikali K:** Data Curation, Formal Analysis, Visualization, Writing – Review & Editing; **Bargul JL:** Supervision, Writing – Review & Editing; **Nduati EW:** Formal Analysis, Supervision, Writing – Review & Editing; **Ndungu FM:** Formal Analysis, Resources, Writing – Review & Editing; **Bejon P:** Formal Analysis, Funding Acquisition, Resources, Supervision, Writing – Review & Editing; **Rayner JC:** Funding Acquisition, Supervision, Writing – Review & Editing; **Abdi AI:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Visualization, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by The Wellcome International Intermediate Fellowship in Public Health and Tropical Medicine, grant number 209289 to AA. SM was supported through the DELTAS Africa Initiative [DEL-15-003] studentship. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107769] and the UK government.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2021 Mwangi SJ *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Mwangi SJ, Gwela A, Mwikali K *et al.* **Impact of *Plasmodium falciparum* small-sized extracellular vesicles on host peripheral blood mononuclear cells [version 2; peer review: 1 approved, 2 not approved]** Wellcome Open Research 2021, 5:197 <https://doi.org/10.12688/wellcomeopenres.16131.2>

**First published:** 21 Aug 2020, 5:197 <https://doi.org/10.12688/wellcomeopenres.16131.1>

**REVISED Amendments from Version 1**

Additional text and references was added in response to the reviewers comments. Everything else remain the same as the originally submitted version.

**Any further responses from the reviewers can be found at the end of the article**

## Introduction

*Plasmodium falciparum* causes almost half a million deaths per year<sup>1</sup>. In the human host, the parasite infects both the liver and red blood cells, but it is the parasite-host interaction during the blood stage that is responsible for pathology. *P. falciparum*-infected red blood cells can interact with the host cells directly, for example through endothelial protein C receptor (EPCR) to induce inflammation<sup>2</sup>, and also indirectly through secreted parasite factors<sup>3-7</sup>.

One way secreted effector molecules are released from cells is through extracellular vesicles (EVs). EVs are double-layered membrane-bound nanoparticles that are released by cells. They are usually classified into two major sub-groups, small-sized and medium-sized extracellular vesicles<sup>8</sup> often termed as exosomes and microvesicles respectively<sup>9,10</sup>. Small-sized extracellular vesicles (sEVs) are vesicles with a diameter of 30–150 nm. They are generated through inward budding of the limiting membrane of late endosomes resulting in the formation of intraluminal vesicles (ILVs). Late endosomes containing many ILVs are called multivesicular bodies (MVBs) which then fuse with cell membranes and release ILVs into the extracellular space as exosomes or sEVs<sup>8,10</sup>. On the other hand, the diameter of the medium-sized EVs (mEVs) range between 100 and 1000 nm and are formed when part of the cell plasma membrane ‘pinches-off’ with part of the cytoplasm and surface receptors/proteins and are released into the extracellular milieu<sup>10</sup>.

EVs have the ability to transfer their packaged signaling competent molecules (including proteins, lipids, nucleic acids, and metabolites) from one cell to another, consequently modifying the properties of the recipient target cell(s)<sup>9,11-13</sup>. Research in the pathophysiology of several diseases such as cancer<sup>12,14,15</sup> and infectious diseases<sup>16-19</sup> provide evidence for a role of EVs in mediating intercellular interactions<sup>9,16-20</sup>. Tumor- and pathogen-derived EVs have been shown to have the ability to abrogate the host immunological defense mechanisms as a way of evading immune responses within the host<sup>19,21-24</sup>.

In the context of malaria, *P. falciparum* EVs (*Pf*EVs) have a role in intercellular communication<sup>25</sup> as well as in inducing sexual commitment<sup>16,17</sup>. Extracellular vesicles reflect the molecular phenotype of the cells releasing them<sup>12</sup>. Analysis of the impact of host-parasite interactions mediated by *Pf*EVs may improve our understanding of the pathogenesis of severe malaria and the mechanisms through which the parasite modulates the host immune response. Furthermore, proteomic analysis revealed that *Pf*EVs are enriched in parasite proteins involved in

interaction with the host cells<sup>16,26</sup> and have been shown to induce inflammation<sup>16</sup> and endothelial activation<sup>27</sup> and its plasma circulating level to increase with severity of the infection<sup>28</sup>. However, to date, all studies on the impact of *Plasmodium* EVs on host immune response have been performed using either rodent malaria<sup>29-31</sup> or using long-term laboratory-adapted *P. falciparum* isolates<sup>16,32</sup>. Our study is the first to use *P. falciparum* clinical isolates. The quantity and repertoire of the content of *Pf*EVs from clinical isolates appears to be different from that of long-term laboratory-adapted parasite isolates<sup>26</sup> and this may affect their functional impact on host immune cells. In this study, we compared the functional impact of *Pf*sEVs and the autochthonous *Pf*iRBCs of a clinical isolate adapted to short-term culture (<70 cycles) on human peripheral blood mononuclear cells (PBMC).


## Methods

### *Plasmodium falciparum* isolate

A Kenyan *P. falciparum* clinical parasite isolate (unique lab identifier, 9215) was used in this study. This isolate was obtained from a child admitted at Kilifi County Hospital with respiratory distress<sup>33</sup> and was adapted to *in vitro* culture (<70 cycles) and used in previous studies<sup>34,35</sup>. Isolate 9215 was renamed to *Pf*KE12 in unpublished genome data<sup>36</sup>.

### Harvesting and processing of parasite culture media for isolation of *Pf*sEVs

*Pf*KE12 was grown under standard culturing conditions<sup>37</sup>. Mycoplasma contamination was routinely monitored using PCR. The parasite cultures were tightly synchronized using D-sorbitol (Sigma) treatment and bulked up to six flasks, each containing 500 µl packed cell volume at 7% parasitemia. These cultures were grown in 40 ml of complete culture media, (RPMI 1640 [sigma] + L-glutamine [2mM] + HEPES [37.5mM] + D-glucose [0.2%v/v] + gentamicin [25µg/ml] + sodium-hypoxanthine [50µg/ml]) (all from Gibco) supplemented with 0.25% Albumax-II (Gibco) that had previously been depleted of sEVs by ultracentrifugation at 150,000×g for 2 hours. The culture media added at an early ring stage was harvested after 24 hours when the parasites were in the mature trophozoite stage (herein referred to as the rings-to-trophozoite or the RT sample). In this study, the culture-conditioned media (CCM) from the RT sample was harvested as previously described<sup>26</sup> and is shown in Figure 1A. Briefly, the parasite culture was transferred to a 50-ml Falcon tube and centrifuged at 440×g for 5 minutes to pellet down RBCs and the supernatant transferred to a new 50-ml falcon tube. The supernatant (CCM) was then centrifuged once at 440×g for 5 minutes to remove any remaining RBCs and the supernatant transferred into a new 50-ml Falcon tube. This was followed by centrifugation twice at 2,000×g for 10 minutes, once at 3,600×g for 10 minutes and once at 15,000×g for 30 minutes to pellet out mEVs. The mEVs pellet was then resuspended in 1×PBS and stored at -80°C until use (this pellet will be referred to as *Pf*mEVs if from *P. falciparum* CCM). The resultant supernatant from the final centrifugation at 15,000×g above was filtered through a 0.2-µm filter (FiltroSpurS, Sarstedt) and stored at -80°C until use. Uninfected red blood cells (uRBCs) freshly obtained from a donor or stored for a month at 4°C were also cultured in six flasks each containing 500µl packed cells and 40ml culture



**Figure 1. EV isolation procedure and the protein concentration of the isolated EVs.** (A) Schematics showing the procedure for EV isolation from culture conditioned media. (B) The bar graphs show the crude protein concentration of medium EVs (mEVs) and small EVs (sEVs) isolated from *P. falciparum* (Pf) infected and uninfected RBC (uRBCs) culture conditioned media; PfmEVs, uRBCs-mEVs, PfsEVs and uRBCs-sEVs using Bradford assay. Each bar represent data from three biological replicates. \*Significant difference using Mann-Whitney U-Test.

media at 37°C in for either 24 or 48 hours, the CCM harvested and processed as described for the *P. falciparum*-infected red blood cells cultures. The uRBCs used for CCM harvesting were of the same batch as the one used in maintaining the iRBCs cultures for *P. falciparum* CCM harvesting.

#### Isolation of sEVs from culture-conditioned media

The 0.2-μm-filtered CCM supernatant stored at -80°C was thawed on ice and transferred under sterile conditions into quick-seal ultracentrifuge tubes (Beckman Coulter cat# 343322) that were then heat-sealed. The sealed tubes were next ultracentrifuged using Optima XE-90 ultracentrifuge in a pre-cooled (4°C) 70.1Ti fixed-angle rotor (Beckman Coulter) at 150,000×g for 2 hours at 4°C (Figure 1A). This approach is likely to enrich for sEVs, based on their size and the 0.2-μm filter cut-off and henceforth, referred to as PfsEVs. The pellet was then washed twice by re-suspending in ice-cold 1× PBS followed by ultracentrifugation at 150,000×g for 2 hours at 4°C between washes. The final PfsEVs pellet was re-suspended in 400 μl of ice-cold 1× PBS, aliquoted and stored at -80°C until use (Figure 1A). The Bradford protein assay was used to determine the protein concentration in the PfsEVs following the manufacturer's instructions (Figure 1A). The isolated PfsEVs were also tested for mycoplasma contamination. The processed uRBCs' CCM was similarly subjected to the above isolation process to obtain the equivalent of PfsEVs from uninfected RBCs (uRBCs-sEVs).

#### Isolation of infected red blood cells (iRBCs)

*Plasmodium falciparum*-infected RBCs (PfiRBCs) were isolated from the *P. falciparum* culture using magnetic-activated cell sorting (MACS) columns (Miltenyi Biotec). Tightly synchronized culture at 7% parasitemia was taken through MACS separation columns during the late trophozoite stages. The MACS-purified iRBCs were then washed twice with incomplete culture media (RPMI 1640[Sigma] + L-glutamine[Gibco] + HEPES[Gibco] + D-glucose[Gibco] + gentamicin[Gibco] + sodium-hypoxanthine[Gibco]) and the supernatant aspirated out. Glycerolyte was added to the MACS-purified PfiRBCs at 3:1 vol/vol ratio, stored at -80°C in small aliquots until use. Uninfected RBCs (uRBCs) that were cultured for CCM harvesting (as explained above) were washed twice in incomplete culture media (after CCM harvesting) and stored in appropriate volumes of glycerolyte in -80°C until use.

#### PBMC isolation

PBMC were obtained from 20 adult Kenyan volunteers. Fresh heparinized whole blood (~20-30 mls) was obtained from each consenting adult donor for plasma and PBMC isolation. The blood was centrifuged at 440×g for 5 minutes to remove plasma that was then stored at -80°C. The cells were topped-up with a wash buffer, R0 (RPMI 1640 supplemented with L-glutamine[2nm] and Penicillin/Streptomycin [1U/ml], Gibco) equivalent to 5 volumes of the cell pellet the plasma volume aspirated out.

The blood was then layered on Lymphoprep™ (Stemcell Technologies) at a Lymphoprep to blood ratio of 1:2 and centrifuged at 440×g for 20 minutes at room temperature. The PBMC layer between the Lymphoprep and media was aspirated out into a new 50ml Falcon tube and washed twice in R0 at 360×g for 7 minutes and 4°C. The washed PBMC were resuspended in ice-cold freezing medium (10% dimethyl sulfoxide (DMSO) in fetal calf serum (FCS)) and stored overnight at -80°C in Mr. Frosty (Thermo Scientific) before being transferred to liquid nitrogen until use. Prior to storage or use, PBMC number and viability was determined by Trypan blue exclusion using the Vi-CELL XR 2.03 counter (Beckman Coulter, USA) and/or hemocytometer chamber.

### PBMC stimulation assays

A 1×10<sup>6</sup> PBMC per stimulation condition were co-cultured with *Pf*iRBC or *Pf*sEV in 96-well U-bottomed cell culture plates (Greiner Bio-One).

The stimulation conditions included: *Pf*sEVs added at a determined concentration of 20µg/ml based on consideration from a previous experiment by Mantel *et al.*<sup>16</sup>, and 1×10<sup>6</sup> MACS-purified iRBCs (*Pf*iRBCs). The positive controls were *Staphylococcal* enterotoxin B (SEB) at 2.5 µg/ml as a polyclonal activator and CpG-ODN (2.5 µg/ml). Lipopolysaccharide (LPS) at 200 ng/ml was included as an additional positive control for a subset of experiments that involved PBMC from 12 donors. Co-culture wells with (PBMC + cell growth medium only) and (PBMC + 1×10<sup>6</sup> uRBC) were included in each experiment as negative controls. These uRBCs were of the same batch as that used to culture the parasites. The PBMC were co-incubated with the stimulants for 18 hours in a humidified incubator at 37°C and 5% CO<sub>2</sub>.

Cells were harvested after 18 hours stimulation, washed in fluorescence activated cell sorting (FACS) buffer (1× PBS + 5% FCS + 0.01% sodium azide) and then stained with 30 µl of fluorescently-labeled antibody cocktail containing: Phycoerythrin (PE)-Cyanine (Cy) 5-conjugated anti-human CD3 [BioLegend, Cat#: 300410, Clone: UCHT1]/Brilliant Violet (BV)-785 anti-human CD3 [BioLegend, Cat#: 317330, Clone: OKT3], PE-Cy7-conjugated anti-human CD4 [BioLegend, Cat#: 317414, Clone: OKT4], PE-CF594 Mouse anti-human CD8, [BD Biosciences, Cat#: 562282 Clone: RPA-T8]/Alexa Fluor 700-conjugated anti-human CD8a [BioLegend, Cat#: 301028 Clone: RPA-T8, 0.5mg/ml], Pacific Blue-conjugated anti-human CD19 [BioLegend, Cat#: 982404, Clone: HIB19, 200µg/ml]/PE-Cy5 anti-human CD19 [BioLegend Cat#: 302210, Clone: HIB19], BV650-conjugated anti-human CD14 [BioLegend, Cat#: 301836, Clone: M5E2], Alexa Fluor 488-conjugated anti-human CD69 [BioLegend, Cat#: 310916, Clone: FN50], BV711-conjugated anti-human CD25 [BioLegend, Cat#: 302636, Clone: BC96], and Fixable Viability Dye eFluor® 780, [eBioscience, Cat#: 65-0865-18]. All antibodies were used at a 1:200 dilution apart from BV711 anti-human CD25 that was used at a 1:100 dilution. (Those antibodies without indicated concentrations have either lot-specific concentrations or pre-diluted for use at recommended volume per test).

The cells were stained for 30 minutes at 4°C and washed twice before being re-suspended in 300 µl of FACS-flow buffer (BD Biosciences). Cells were acquired on the LSRFortessa™ cell analyzer (BD Biosciences). At least 100,000 events were acquired per stimulation condition and at least 170,000 events for the *Pf*iRBCs and uRBCs conditions since these had an extra cell lysis step prior to staining. Data were analyzed using FlowJo® software version 10.0 (Tree Star).

### ELISA and LUMINEX assays

Cell free culture supernatants from the stimulation assays (above) were aspirated and stored at -20°C prior to cytokine analysis. Supernatants used for this assay were all from the subset of experiments where LPS was included as an additional positive control condition. Supernatants were thawed on ice and used to quantify a total of 29 analytes; IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-15, IL-17A, TNF-α, TNF-β, GM-CSF, G-CSF, IL-12 (p40), IL-12 (p70), IL-8, EGF, IP-10 (CXCL10), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), VEGF, and Eotaxin (CCL11). Analytes were measured using the MILLIPLIX Human Cytokine/Chemokine Magnetic bead 29-Plex assay (catalogue #HCYTMAG-60K-PX29) from Merck-Millipore following the manufacturer's instructions. A total of 25 µl of the culture supernatant was diluted 1:5 times in assay medium and incubated with 25 µl of anti-cytokine antibody-coupled magnetic beads for 2 hours at room temperature while shaking at 500 rpm in the dark. The beads were then washed twice and incubated with 25 µl of biotinylated detector antibody for 1 hour at room temperature, before addition of streptavidin R-phycoerythrin and further incubation for 30 minutes (between each washing step, the beads were retained in the plate using a magnetic separator). After a final wash, beads were re-suspended in 150 µl of LUMINEX Drive Fluid and 100 beads counted for each cytokine in a MAGPIX reader running on MAGPIX xPOTENT 4.2 software (Luminex Corporation). Analyte concentrations were calculated (via Milliplex Analyst v5.1 [VigeneTech]) from the mean fluorescence intensity expressed in pg/ml using standard curves with known concentrations of each analyte. In addition to the 29 analytes measured using the Luminex platform, TGF-β levels were measured using an ELISA kit (ThermoFisher; cat# BMS249-4) following the manufacturer's protocol.

### Anti-schizont antibody ELISA

Frozen plasma samples from the PBMC donors were thawed and used in an anti-schizont ELISA to determine prior exposure to malaria. ELISA plates were coated with 100 µl of 1:6000 diluted crude schizont extract/lysate and incubated overnight at 4°C. The plates were then aspirated and blocked with 1% skimmed milk and incubated for 5 hours at room temperature with washes between each step. This was followed by addition and an overnight incubation with 100µl of the 1:1000 diluted plasma, 3 hours incubation at room temperature with 100 µl of HRP-conjugated Rabbit anti-human IgG (Thermo Scientific) and final incubation with 100µl of the o-Phenylenediamine dihydrochloride (OPD) substrate for 15 minutes. The reaction was stopped with 25 µl of 2 M H<sub>2</sub>SO<sub>4</sub> and the plates read at

492 nm on a Synergy 4 (Bio Tek) plate reader, recording the samples' optical densities (OD).

### Data analysis

The flow cytometry data from the FlowJo® analysis and ELISA data analyses were performed using Prism 6.01 (GraphPad). Mann-Whitney U-test was used to compare continuous variables between two conditions. The chemokine/cytokine dataset was transformed using Yeo Johnson transformation<sup>38</sup> for the data to conform to normal distribution and t-test was used to compare between two conditions. The unstimulated PBMC culture medium (media) was used as the background negative control condition for both *PfsEVs* and *PfiRBCs*. For *PfiRBCs*, relative comparison to uRBCs condition was also shown. To test the impact of prior malaria exposure on PBMC response to *PfsEVs* and *PfiRBCs* stimulation, the anti-schizont IgG response in the contemporaneous plasma sample of each PBMC sample was related, using Spearman's rank correlation, to the induced expression of the activation markers on CD4<sup>+</sup>, CD8<sup>+</sup>, CD19<sup>+</sup>, CD14<sup>+</sup> cells following stimulation with either *PfsEVs* or *PfiRBCs*. Due to small sample size (N=8), the same test was not done for the cytokine/chemokine data. For all tests, *P* values were considered significant if <0.05.

### Ethical statement

Ethical approval was obtained from Kenya Medical Research Institute Scientific and Ethical Review Unit (KEMRI/SERU/CGMRC/022/3149), and written informed consent was obtained from the PBMC sample donors. The study methods were carried out in accordance with the approved guidelines.

### Results

Infected RBCs release a greater quantity of small-sized extracellular vesicles (sEVs) than uninfected RBCs mEVs and sEVs were isolated from culture conditioned media (CCM) of *PfiRBCs* from a Kenyan clinical isolate (*PfjKE12*) and uRBCs as shown in Figure 1a. We have previously demonstrated successful isolation of sEVs from *PfiRBCs* CCM by transmission electron microscopy<sup>26</sup> using the protocol described in the methods and schematically represented in Figure 1a. In this study, we used the isolated mEVs and sEVs protein concentration as a proxy for EV abundance<sup>8</sup>. As shown in Figure 1B, the mean protein concentration of mEVs from *PfiRBCs* CCM (*PfmEVs*) was ~4.9-fold higher than that of uRBCs (uRBCs-mEVs), perhaps as result of a combination of the additional parasite-derived proteins packaged into the mEVs on top of those derived from the host and increased rate of mEVs release due to the infection.

The mean protein concentration of the sEV fraction from fresh or aged uRBCs CCM was negligible (Figure 1B), consistent with previous reports that show mature RBCs primarily release mEVs (microvesicles) but not sEVs (exosomes)<sup>39</sup>.

Both *PfiRBCs* and *PfsEVs* induced expression of at least one of the activation markers on T cells, B cells and monocytes

PBMC samples from 20 healthy Kenyan adult donors were co-cultured with *PfiRBCs* and *PfsEVs* from the same isolate

(*PfjKE12*). In addition to the test conditions we included unstimulated control (PBMC' culture medium) and uRBCs as negative controls; and CpG/SEB as positive control conditions. For 12 of the 20 PBMC samples (6 from high and 6 from low/no malaria transmission residents), LPS was also included as an additional positive control condition. Our inability to detect meaningful protein content in the sEV fraction isolated from uRBCs CCM equivalent to the *PfsEVs* used in this study excluded the possibility of using uRBC-sEVs as a negative control in the PBMC stimulation experiments.

Following co-culturing of the PBMC with the stimulants, the expression of the surface activation markers, CD25 and CD69 on T cells, B cells and monocytes was assessed by flow cytometry and analysed using FlowJo Software v.10.6.2. *Extended data*, Figure S1<sup>40</sup> shows the FlowJo gating strategy to enumerate different cell populations. Raw flow cytometry files are available as *Underlying data*<sup>40</sup>.


*PfsEVs* induced significantly higher expression of CD25 on CD4<sup>+</sup> T cells, CD19<sup>+</sup> B cells and CD14<sup>+</sup> compared to the background media condition (Figure 2A–C). In contrast, the effect of *PfiRBCs* was apparent only on the antigen-presenting cells, CD19<sup>+</sup> B-cells and CD14<sup>+</sup> monocytes (Figure 2B, C) with a significantly higher CD25 expression relative to the background condition (media or uRBCs).

Both *PfsEVs* and *PfiRBCs* induced a higher expression of CD69 on CD4<sup>+</sup>, CD8<sup>+</sup> and CD19<sup>+</sup> relative to the background condition (Figure 2D–F). Additionally, *PfiRBCs* induced significant CD69 expression on CD14<sup>+</sup> cells (Figure 2G). Notably, *PfiRBCs* induced a higher CD69 expression on CD4<sup>+</sup> and CD19<sup>+</sup> cells relative to that induced by *PfsEVs* (Figure 2E, F). Taken together, the above result shows that both *PfsEVs* and *PfiRBCs* can activate T and B cells and monocytes; but *PfsEVs* tended to induce higher expression of the activation marker, CD25 while *PfiRBCs* preferentially induced higher CD69.

To exclude the possibility of low-level Mycoplasma contamination that may be enriched during *PfsEVs* isolation, *PfsEV*-DNA extract was used in a PCR-based test. No contamination was detected (*Extended data*, Figure S2)<sup>40</sup>.

*PfsEVs* and *PfiRBCs* induced common and unique cytokine/chemokine profile

For 8 out of the 20 PBMC samples (4 from high and 4 from low/no malaria transmission residents), levels of 29 different cytokines/chemokines in the culture supernatant induced by each of the stimulants were measured using Luminex. Additionally, TGF-β was measured by ELISA. IL-3, IL-4, and IL-5 levels were below the limit of detection with both *PfsEVs* and *PfiRBCs* (*Extended data*, Figure S3)<sup>40</sup>. The levels of 16 cytokines/chemokines induced by *PfsEVs* and by *PfiRBCs* were not significantly greater than the levels seen in the negative controls using two-sided t-test, however, on one-sided t-test, IL-15 and G-CSF induced by both *PfsEVs* and *PfiRBCs* were significantly higher relative to the background conditions (*Extended data*, Figure S3)<sup>40</sup>. Output ELISA files are available as *Underlying data*<sup>40</sup>.



**Figure 2. Proportion of T cells, B-cells and monocytes expressing the activation markers CD25 and CD69 under the different stimulation conditions.** (A–G) Proportions of CD4<sup>+</sup> T-cells, CD8<sup>+</sup> T-cells, CD19<sup>+</sup> B-cells, and CD14<sup>+</sup> Monocytes expressing the activation markers CD25 (upper panel) and CD69 (lower panel) following PBMC co-culture with *PfsEVs* or *PfiRBCs*. unstimulated PBMC (media) and uRBCs were included as negative control conditions while CpG and SEB were included as positive control conditions. Both *PfsEVs* and *PfiRBCs* conditions was compared to the background media condition. *PfiRBCs* was also compared with uRBCs condition. (\*P-value = 0.01-0.05; \*\*P-value = 0.001-0.01; \*\*\*P-value = 0.0001-0.001; \*\*\*\*P-value <0.0001; the red horizontal lines indicates the median. P-value was calculated using Mann-Whitney U-test).

Of the remaining 11 cytokines/chemokines, significant induction relative to the negative control background was observed with; a) both *PfsEVs* and *PfiRBCs* for MIP1 $\alpha$ , MIP1 $\beta$ , GM-CSF, IL-6, IL-8, and TNF- $\alpha$  (Figure 3A–F), b) *PfsEVs* only for MCP1, IL-10 and IL-17 $\alpha$  (Figure 3G–I) and c) *PfiRBCs* only for IFN- $\gamma$  and IP-10 (Figure 3J–L). Notably, the levels of IFN $\gamma$  and IP-10 induced by *PfiRBCs* were significantly higher than the levels induced by *PfsEVs* (Figure 3J–K), while the concentration of IL-17 $\alpha$  induced by *PfsEVs* tended to be higher than that induced by *PfiRBCs* (p=0.07, Figure 3I). Interestingly, in contrast to most cytokines/chemokines, the level of MCP-1 induced by both *PfiRBCs* and *PfsEVs* was uniquely higher than that induced by LPS (Figure 3G). Additionally, the level of IP-10 induced by *PfiRBCs* was also significantly higher than that induced by LPS (Figure 3K). Overall, both *PfsEVs* and *PfiRBCs* were able to induce various chemokines and cytokines but *PfsEVs* seems to be better in inducing secretion of IL-17 $\alpha$  while *PfiRBCs* was better in inducing IFN- $\gamma$  and IP-10 suggesting that they might have differential abilities in inducing Th17 and Th1 T cell responses, respectively.

#### Exposure to malaria tends to tolerise monocytes responses to *PfsEVs*


Given that malaria exposure has been shown to induce immunological tolerance<sup>41–43</sup>, we related the cell surface activation data to each donor's IgG response to crude schizont extract using Spearman's rank correlation. As shown in Figure 4, CD25 expression on CD14<sup>+</sup> cells (CD14<sup>+</sup>CD25<sup>+</sup>) following stimulation of the PBMC samples with *PfsEVs* or *PfiRBCs* decreased with

the level of pre-existing anti-schizont IgG in the plasma of each PBMC donor and this association reached significance for *PfsEVs* (rho=-0.51, p=0.02, N=20). Furthermore, anti-schizont IgG level explained 19% of the variation in CD25 expression on CD14<sup>+</sup> monocytes when anti-schizont was used as an explanatory variable in a linear regression model predicting CD14<sup>+</sup>CD25<sup>+</sup> (coeff(95%CI)=-0.28(-0.52,-0.03), p=0.03, adjusted R<sup>2</sup>=19%, N=20). This result suggest malaria exposure tolerizes the host innate immune response to *PfsEVs*. The cytokine/chemokine data was not subjected to the same analysis due to small sample size (N=8).


#### Discussion

In this study we investigated 1) whether *PfsEVs* can induce PBMC activation *in vitro*, specifically by measuring cell surface activation markers and cytokines/chemokines secreted into the culture media following co-culture with PBMC; 2) how the PBMC activation induced by *PfsEVs* compares with that of *PfiRBCs*; and 3) whether prior exposure to malaria among the PBMC donors influences the level of the induced PBMC activation markers.

We showed that both *PfsEVs* and *PfiRBCs* induced T-cells, B-cells, and monocytes to express at least one of the surface activation markers examined relative to the negative control condition. *PfsEVs* showed relatively stronger induction of CD25 expression while *PfiRBCs* preferentially induced CD69 expression, particularly on B-cells. At the cytokine/chemokine level, both induced secretion of several cytokines/chemokines



**Figure 3. Cytokines/chemokines significantly induced after PBMC co-culture with *PfsEVs* or *PfiRBCs*.** Cytokine/chemokine level was determined only in the supernants of 8 out of the 20 PBMC samples co-cultured with the different stimulants. The 8 samples were part of the 12 samples where LPS was included as an additional positive control. \*P-value = 0.01-0.05; \*\*P-value = 0.001-0.01 and \*\*\*P-value = 0.0001-0.001. The red horizontal lines indicate the mean. P-value was calculated using two-sided t-test.



**Figure 4. The impact of prior malaria exposure on PBMC response to *PfiRBCs* and *PfsEVs*.** Correlations between anti-schizont IgG response in the plasma of each PBMC donor and the expression of the activation markers (CD25 and CD69) on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, CD19<sup>+</sup> B cells and CD14<sup>+</sup> monocytes, following co-culture of each donor's PBMC sample with *PfiRBCs* or *PfsEVs* was determined using Spearman's rank correlation. Shown is the rho and p-value (in bracket). Increasing colour intensity indicate stronger association.



but they also showed differential ability to induce secretion of some cytokines. Notably, *PfsEVs* induced secretion of higher levels of IL-17 $\alpha$  relative to the background media and tended to be higher than that induced by *PfiRBCs* (Figure 3I). IL-17 $\alpha$  is known to be secreted by Th17 CD4+ T cells and the cytokines, IL-6 and TGF- $\beta$  have been shown to be able to induce differentiation of naïve CD4 T-cells into Th17 cells *in vitro*<sup>44</sup>. Interestingly, *PfsEVs* also induced significantly higher levels of IL-6 (Figure 3E) but not TGF- $\beta$  (Extended data, Figure S3)<sup>40</sup>. On the other hand, *PfiRBCs* showed superior ability to induce secretion of IFN- $\gamma$  and IP-10 relative to the background uRBCs and even to *PfsEVs* condition when co-cultured with PBMC (Figure 3J–K). IP-10 secretion is driven by a pro-inflammatory cytokine milieu including IFN- $\gamma$ <sup>45</sup>; thus, it is plausible that high levels of IFN- $\gamma$  led to the IP-10 secretion that we identified in response to *PfiRBCs* stimulation.

Hence our interpretation is that *PfsEVs* and *PfiRBCs* can induce differentiation of CD4+ T cells into Th17 and Th1 cells respectively. In a recent study<sup>46</sup>, *PfiRBCs* were shown to induce NK cells to secrete IFN- $\gamma$  while *PfmEVs* could not, which is consistent with the observation made in this study with *PfsEVs* and *PfiRBCs* co-cultured with PBMC. This finding warrants further characterization of the T cell subsets activated by *PfsEVs*, including  $\gamma\delta$  T-cells known to be activated by phosphoantigens in *P. falciparum* culture medium<sup>47</sup>.

We observed *PfiRBCs* could induce significantly higher MCP-1 (CCL2) and IP-10 (CXCL10) compared to LPS when co-cultured with PBMC (Figure 3C, K). This result is consistent with observation previously made with co-culturing of *PfiRBCs* with purified dendritic cells<sup>48</sup>. However, in the previous study<sup>48</sup>, co-culture of *PfiRBCs* with purified dendritic cells could not induce secretion of inflammatory cytokines such as TNF- $\alpha$  and IFN- $\gamma$ <sup>48</sup>. This difference might be explained by the presence of cells such as T cells in PBMC, which could be the source of the TNF- $\alpha$  and IFN- $\gamma$ .

Previously, persistent exposure to malaria infection have been shown to tolerize T and B cell response to malaria antigens<sup>42,43</sup>. In this study we showed, albeit with a small sample size, that the degree of previous malaria exposure (determined by the level of IgG response to crude schizont extract in the plasma of each PBMC donor) was negatively associated with monocyte's response to *PfsEVs* (Figure 4). *PfsEV* interaction with monocytes *in vitro* have been shown to induce inflammatory response<sup>27</sup>, potentially contributing to malaria pathogenesis. Therefore, tolerance to *PfsEVs* following frequent malaria infection may be part of the naturally acquired anti-disease immunity<sup>41</sup>.

We showed that uninfected red blood cells (uRBCs) do not produce sEVs (exosomes) containing quantifiable amount of proteins using a Bradford assay. During the isolations, we used culture conditioned media (CCM) from varied uRBCs ranging from fresh (processed for culture within 1 hour after phlebotomy) to 2 weeks old cultures. By contrast, the mEV fraction from uRBC CCM repeatedly contained quantifiable amount of proteins and this is consistent with the findings of multiple studies<sup>28,49</sup>. This might indicate that uRBCs release sEVs, but with very low

levels of packaged proteins; however, it could alternatively mean that uRBCs primarily release mEVs (microvesicles). The latter interpretation is consistent with previous studies that showed developing red blood cells release sEVs during earlier stage of haematopoiesis, but mature RBCs do not<sup>39,50,51</sup> as they have lost the endocytic pathway that is essential for the biogenesis of sEVs. Despite our view, favoring the possibility of uRBCs not releasing sEVs, we cannot rule out small amount of sEVs released by uRBCs especially reticulocytes contributing to the overall impact of *PfsEVs* on PBMCs which we did not control for.

Our study has several limitations; 1) lack of microscopy or NanoSight evidence demonstrating successful isolation of sEVs in according to ISEV2018 recommendation<sup>8</sup>. However, we have previously<sup>26</sup> isolated EVs whose size and density match those of sEVs using the method used in this study and also validated *P. falciparum* protein marker that can be targeted for western blot analysis does not exist currently, 2) while we used multiple PBMC donors to generate these results, this study used only one *P. falciparum* isolate and, therefore, we cannot conclusively determine if the results we obtained will remain similar if the number of isolates was increased for diversity. Different parasites have been shown to display a difference in virulence with studies demonstrating that this virulence can be transferred to non-virulent parasite phenotypes via secreted EVs<sup>18,19</sup>. Drawing analogy from these experiments, it would be interesting to see if the phenomena we observe are consistent across isolates of *P. falciparum* with different levels of virulence, and whether any differences can be correlated with differences in protein or RNA content within the sEVs, 3) *PfsEVs* impact on PBMC *in vivo* might be different from that observed under *in vitro* experiment since *PfsEVs* are expected to interact with multiple host cells including endothelial cells leading to a more complex interaction and outcome. More functional, proteomic and transcriptomic analysis of the *PfsEVs* is clearly needed.

## Data availability

### Underlying data

Harvard Dataverse: Replication Data for: Impact of Plasmodium falciparum small-sized extracellular vesicles (*PfsEVs*) on host peripheral blood mononuclear cells. <https://doi.org/10.7910/DVN/QXUFQ740>.

This project contains the following underlying data:

- Folder 1\_Flow cytometry fsc files\_PfEV\_PBMC\_paper\_anon.zip. (FCS files generated from flow cytometry experiments.)
- SMwangi\_PfsEV\_Data\_files\_anon.zip. (XLSX files containing raw data from cytokine analysis and ELISA experiments).
- SMwangi\_PfsEVs\_Readme.txt. (README file.)
- SMwangi\_PfsEVs\_Codebook.pdf. (Dataset codebook.)

### Extended data

Harvard Dataverse: Replication Data for: Impact of Plasmodium falciparum small-sized extracellular vesicles (*PfsEVs*) on host peripheral blood mononuclear cells. <https://doi.org/10.7910/DVN/QXUFQ740>.

File 'supplementary\_material\_PfEV\_PBMC\_paper.pdf' contains the following extended data:

- Figure S1: Gating strategy.
- Figure S2: Gel electrophoresis image after PCR to test for Mycoplasma contamination in *P. falciparum* cultures and isolated PfEVs.
- Figure S3: Cytokines/chemokines not significantly induced following PBMC co-culture with PfEVs or PfIRBCs .

Data are available under the terms of the [Creative Commons Attribution 4.0 International license \(CC-BY 4.0\)](#).

## Acknowledgements

We are grateful to the adult volunteers who donated the blood samples that was used to isolate the PBMC samples used in this study. This paper was published with the permission of the Director of Kenya Medical Research Institute.

## References

1. WHO: **World Malaria Report 2019**. 2019. [Reference Source](#)
2. Turner L, Lavstsen T, Berger SS, et al.: **Severe malaria is associated with parasite binding to endothelial protein C receptor**. *Nature*. 2013; **498**(7455): 502–505. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. MacDonald SM, Bhisutthibhan J, Shapiro TA, et al.: **Immune mimicry in malaria: *Plasmodium falciparum* secretes a functional histamine-releasing factor homolog *in vitro* and *in vivo***. *Proc Natl Acad Sci U S A*. 2001; **98**(19): 10829–10832. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Tripathi AK, Sha W, Shulaev V, et al.: ***Plasmodium falciparum*-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium**. *Blood*. 2009; **114**(19): 4243–4252. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Sun T, Holowka T, Song Y, et al.: **A *Plasmodium*-encoded cytokine suppresses T-cell immunity during malaria**. *Proc Natl Acad Sci U S A*. 2012; **109**(31): E2117–2126. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Abdi AI, Fegan G, Muthui M, et al.: ***Plasmodium falciparum* antigenic variation: relationships between widespread endothelial activation, parasite PfEMP1 expression and severe malaria**. *BMC Infect Dis*. 2014; **14**: 170. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Hanson J, Lee SJ, Hossain MA, et al.: **Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study**. *BMC Med*. 2015; **13**: 122. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Thery C, Witwer KW, Aikawa E, et al.: **Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines**. *J Extracell Vesicles*. 2018; **7**(1): 1535750. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Thery C, Ostrowski M, Segura E: **Membrane vesicles as conveyors of immune responses**. *Nat Rev Immunol*. 2009; **9**(8): 581–593. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Raposo G, Stoorvogel W: **Extracellular vesicles: exosomes, microvesicles, and friends**. *J Cell Biol*. 2013; **200**(4): 373–383. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Schorey JS, Cheng Y, Singh PP, et al.: **Exosomes and other extracellular vesicles in host-pathogen interactions**. *EMBO Rep*. 2015; **16**(1): 24–43. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Kalluri R: **The biology and function of exosomes in cancer**. *J Clin Invest*. 2016; **126**(4): 1208–1215. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Zhao H, Yang L, Baddour J, et al.: **Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism**. *Elife*. 2016; **5**: e10250. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Costa-Silva B, Aiello NM, Ocean AJ, et al.: **Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver**. *Nat Cell Biol*. 2015; **17**(6): 816–826. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Hodgson SH, Ewer KJ, Bliss CM, et al.: **Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals**. *J Infect Dis*. 2015; **211**(7): 1076–1086. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Mantel PY, Hoang AN, Goldowitz I, et al.: **Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system**. *Cell Host Microbe*. 2013; **13**(5): 521–534. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Regev-Rudzki N, Wilson DW, Carvalho TG, et al.: **Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles**. *Cell*. 2013; **153**(5): 1120–1133. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Twu O, de Miguel N, Lustig G, et al.: ***Trichomonas vaginalis* exosomes deliver cargo to host cells and mediate host-parasite interactions**. *PLoS Pathog*. 2013; **9**(7): e1003482. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Szempruch AJ, Sykes SE, Kieft R, et al.: **Extracellular Vesicles from *Trypanosoma brucei* Mediate Virulence Factor Transfer and Cause Host Anemia**. *Cell*. 2016; **164**(1–2): 246–257. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Li J, Liu K, Liu Y, et al.: **Exosomes mediate the cell-to-cell transmission of IFN- $\alpha$ -induced antiviral activity**. *Nat Immunol*. 2013; **14**(8): 793–803. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Filipazzi P, Burdek M, Villa A, et al.: **Recent advances on the role of tumor exosomes in immunosuppression and disease progression**. *Semin Cancer Biol*. 2012; **22**(4): 342–349. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Lambert U, Silverman JM, Nandan D, et al.: **Secreted virulence factors and immune evasion in visceral leishmaniasis**. *J Leukoc Biol*. 2012; **91**(6): 887–899. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Buck AH, Coakley G, Simbari F, et al.: **Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity**. *Nat Commun*. 2014; **5**: 5488. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Swatler J, Dudka W, Bugajski L, et al.: **Chronic myeloid leukemia-derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells**. *Eur J Immunol*. 2020; **50**(4): 606–609. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Correa R, Coronado L, Caballero Z, et al.: **Extracellular vesicles carrying lactate dehydrogenase induce suicide in increased population density of *Plasmodium falciparum in vitro***. *Sci Rep*. 2019; **9**(1): 5042. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Abdi A, Yu L, Goulding D, et al.: **Proteomic analysis of extracellular vesicles from a *Plasmodium falciparum* Kenyan clinical isolate defines a core parasite secretome [version 2; peer review: 2 approved, 1 approved with reservations]**. *Wellcome Open Res*. 2017; **2**: 50. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Mantel PY, Hjelmqvist D, Walch M, et al.: **Infected erythrocyte-derived extracellular vesicles alter vascular function via regulatory Ago2-miRNA complexes in malaria**. *Nat Commun*. 2016; **7**: 12727. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Nantakomol D, Dondorp AM, Krudsood S, et al.: **Circulating red cell-derived microparticles in human malaria**. *J Infect Dis*. 2011; **203**(5): 700–706. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Martin-Jaurar L, Nakayasu ES, Ferrer M, et al.: **Exosomes from *Plasmodium***

- yoelii-infected reticulocytes protect mice from lethal infections.** *PLoS One*. 2011; **6**(10): e26588.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Demarta-Gatsi C, Rivkin A, Di Bartolo V, *et al.*: **Histamine releasing factor and elongation factor 1 alpha secreted via malaria parasites extracellular vesicles promote immune evasion by inhibiting specific T cell responses.** *Cell Microbiol*. 2019; **21**(7): e13021.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Couper KN, Barnes T, Hafalla JCR, *et al.*: **Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation.** *PLoS Pathog*. 2010; **6**(1): e1000744.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Sisquella X, Ofir-Birin Y, Pimentel MA, *et al.*: **Malaria parasite DNA-harboring vesicles activate cytosolic immune sensors.** *Nat Commun*. 2017; **8**(1): 1985.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Marsh K, Forster D, Waruiru C, *et al.*: **Indicators of life-threatening malaria in African children.** *N Engl J Med*. 1995; **332**(21): 1399–1404.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Tan J, Pieper K, Piccoli L, *et al.*: **A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens.** *Nature*. 2016; **529**(7584): 105–109.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Pieper K, Tan J, Piccoli L, *et al.*: **Public antibodies to malaria antigens generated by two LAIR1 insertion modalities.** *Nature*. 2017; **548**(7669): 597–601.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Otto TD, Assefa SA, Böhme U, *et al.*: **Evolutionary analysis of the most polymorphic gene family in falciparum malaria [version 1; peer review: 1 approved, 2 approved with reservations].** *Wellcome Open Res*. 2019; **4**: 193.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science*. 1976; **193**(4254): 673–675.  
[PubMed Abstract](#) | [Publisher Full Text](#)
38. In-Kwon Yeo RAJ: **A new family of power transformations to improve normality or symmetry.** *Biometrika*. 2000; **87**(4): 954–959.  
[Publisher Full Text](#)
39. Kuo WP, Tigges JC, Toxavidis V, *et al.*: **Red Blood Cells: A Source of Extracellular Vesicles.** *Methods Mol Biol*. 2017; **1660**: 15–22.  
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Mwangi SJ, Abdi AI: **Replication Data for: Impact of Plasmodium falciparum small-sized extracellular vesicles (PfsEVs) on host peripheral blood mononuclear cells.** Harvard Dataverse, V3, 2020.  
<http://www.doi.org/10.7910/DVN/QXUFQ7>
41. Langhorne J, Ndungu FM, Sponaas AM, *et al.*: **Immunity to malaria: more questions than answers.** *Nat Immunol*. 2008; **9**(7): 725–732.  
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Illingworth J, Butler NS, Roetynck S, *et al.*: **Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion.** *J Immunol*. 2013; **190**(3): 1038–1047.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Bediako Y, Ngoi JM, Nyangweso G, *et al.*: **The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum - an epidemiological "natural experiment".** *BMC Med*. 2016; **14**(1): 143.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Bettelli E, Carrier Y, Gao W, *et al.*: **Reciprocal developmental pathways for the generation of pathogenic effector T<sub>H</sub>17 and regulatory T cells.** *Nature*. 2006; **441**(7090): 235–238.  
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Luster AD, Ravetch JV: **Biochemical characterization of a gamma interferon-inducible cytokine (IP-10).** *J Exp Med*. 1987; **166**(4): 1084–1097.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Ye W, Chew M, Hou J, *et al.*: **Microvesicles from malaria-infected red blood cells activate natural killer cells via MDA5 pathway.** *PLoS Pathog*. 2018; **14**(10): e1007298.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Guenet M, Loizon S, Howard J, *et al.*: **Phosphoantigen Burst upon Plasmodium falciparum Schizont Rupture Can Distantly Activate Vγ9Vδ2 T Cells.** *Infect Immun*. 2015; **83**(10): 3816–3824.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Gotz A, Tang MS, Ty MC, *et al.*: **Atypical activation of dendritic cells by Plasmodium falciparum.** *Proc Natl Acad Sci U S A*. 2017; **114**(49): E10568–E10577.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Donadee C, Raat NJH, Kanas T, *et al.*: **Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion.** *Circulation*. 2011; **124**(4): 465–476.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Johnstone RM, Adam M, Hammond JR, *et al.*: **Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes).** *J Biol Chem*. 1987; **262**(19): 9412–9420.  
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Blanc L, Liu J, Vidal M, *et al.*: **The water channel aquaporin-1 partitions into exosomes during reticulocyte maturation: implication for the regulation of cell volume.** *Blood*. 2009; **114**(18): 3928–3934.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Peer Review Status:   


---

## Version 2

Reviewer Report 13 May 2021

<https://doi.org/10.21956/wellcomeopenres.18482.r43460>

© 2021 Spadafora C et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 **Carmenza Spadafora** 

Center of Cellular and Molecular Biology of Diseases, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), City of Knowledge, Apartado, Panama, Panama  
**Ricardo Correa**

International Centre of Biotechnology and Genetic Engineering (ICGEB), Trieste, Italy

While I appreciate that authors have tried to address the points that they could without having to go back to experimentation, I still see grave issues that certainly cannot be solved without repeating experiments. Their results might be true, which is why I first approved with reservations, in the hopes that new experiments would be provided, with the right methodology. But the work, as it is, is not acceptable as such. Even if the results were true, a report with work that does not adhere to strict scientific criteria should not be endorsed by the scientific community. In this case, the characterization of the EVs is of utmost importance. The authors argue that there are no established markers for *P. falciparum* EVs, but in all the diverse publications about them reported in the last seven years, the use of proteins such as PfRESA, PfMSP1, PfAMA1, PfEMP1 and others has been validated. There should be enough choice of proteins to procure one that could have been used in a western blot. This would at least warrant the identity of the EVs.

Another medullar problem the experiments in the work presented here have is that the collected EVs were never counted, so there is not an EV concentration that can be compared between infected and uninfected erythrocytes. The authors base their findings in measurements done on proteins acquired in a supernatant of cell centrifugations, which can have all kinds of debris that will count and/or confound the measurement of protein concentration, invalidating the comparisons. I would also like to note that what Correa *et al* mentioned about extracting EVs from uninfected erythrocytes was that the number of them in a given amount of culture was 3X less than those coming from *P. falciparum* infected ones. They are certainly less, but countable. Given that the authors have not satisfied the minimum established standards of EV studies, I regret having to not approve this paper.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Parasitology, Plasmodium falciparum Exovesicles, Drug Discovery, Biophysics of Plasmodium falciparum

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to state that we do not consider it to be of an acceptable scientific standard, for reasons outlined above.**

---

### Version 1

Reviewer Report 10 December 2020

<https://doi.org/10.21956/wellcomeopenres.17707.r41183>

© 2020 Combes V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



#### Valery Combes

Malaria and Microvesicles Research Group, School of Life Sciences, Faculty of Sciences, University Technology of Sydney, Sydney, New South Wales, Australia

This article by Mwangi et al explore the effect of extracellular vesicles (EVs) released by Plasmodium falciparum infected red blood cells on PBMC.

They use a P falciparum clinical isolate from a child with severe malaria. This is interesting as the study does not use one of the laboratory strains such as 3D7 but a lab-adapted isolate.

The introduction is brief and covers the main studies on the effects of EVs in vitro.

I have several comments and questions about the methods and the interpretation of the results.

- There is no size or phenotypic characterisation of the EVs. How can the authors be sure they isolated the right population? This is a very important criteria that needs to be addressed as recommended by the Extracellular vesicle society guidelines for publications on extracellular vesicles.
- In the results the authors mentioned that because they could not detect “meaningful” protein content in u-EVs they did not use them in the experiments. It is expected that the uRBCs will release less EVs than the Pf-RBCs. Why weren't the number of uRBCs used to produce u-EVs increased so equivalent numbers of EVs could be used in the stimulation experiments?
- It is my opinion that the conclusion on the effects of the Pf-EVs are partially incorrect as the statistical analyses were performed against the wrong control. Pf-EVs should be compared to u-EVs. EVs are readily taken up by PBMC and unlike normal media, u-EVs are likely to have a certain effect on the response of the PBMC
- Minor comment: figures 2 and 3 don't show statistical differences with the positive controls.

Is that normal?

- The cytokine and chemokine results are normalised using the yeo Johnson transformation. Although this method is used in clinical experiments could the authors explain why it was used on such a small number of patients. Also this method should be referenced and the text should explain what is the aim of this transformation and what it is normalised against.
- How were the 12 or 8 patients used in the different experiments chosen? were there criteria to ensure homogeneity of the populations or were the samples randomised?
- Minor comment: y axis on the graphs of figure 2 could be changed to have 2 segments to allow a better representation of the important groups.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Partly

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** severe malaria, extracellular vesicles, in vitro models

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.**

Author Response 18 Mar 2021

**Abdirahman Abdi**, KEMRI-Wellcome Trust, CGMRC, Kilifi, Kenya

We thank the reviewer for useful comments. Below we attempted to address the concerns raised by the review.

This article by Mwangi et al explore the effect of extracellular vesicles (EVs) released by Plasmodium falciparum infected red blood cells on PBMC.

They use a P falciparum clinical isolate from a child with severe malaria. This is interesting as the study does not use one of the laboratory strains such as 3D7 but a lab-adapted isolate.

The introduction is brief and covers the main studies on the effects of EVs in vitro.

I have several comments and questions about the methods and the interpretation of the results.

- There is no size or phenotypic characterization of the EVs. How can the authors be sure they isolated the right population? This is a very important criteria that needs to be addressed as recommended by the Extracellular vesicle society guidelines for publications on extracellular vesicles.

**Reply:** *We agree with the reviewer that this is a limitation of the study and we have included a sentence to indicate this limitation (page 14, line 21-25).*

- In the results the authors mentioned that because they could not detect “meaningful” protein content in u-EVs they did not use them in the experiments. It is expected that the uRBCs will release less EVs than the Pf-RBCs. Why weren't the number of uRBCs used to produce u-EVs increased so equivalent numbers of EVs could be used in the stimulation experiments?

**Reply:** *A good suggestion but that is exactly what we did. We used uRBC culture conditioned media obtained from six flasks each containing 500µl packed cells in 40ml media (adding up to 240ml media incubated with 3ml packed RBCs). Additional text was included to clarify this (page 6, line 16-17)*

- It is my opinion that the conclusion on the effects of the Pf-EVs are partially incorrect as the statistical analyses were performed against the wrong control. Pf-EVs should be compared to u-EVs. EVs are readily taken up by PBMC and unlike normal media, u-EVs are likely to have a certain effect on the response of the PBMC

**Reply:** *Ideally, sEVs from uRBCs would have been the appropriate control but our attempt to isolate sEVs from uRBCs has not been successful and it is highly likely that uRBCs do not release sEVs or exosomes. We believe that this makes sense given the proposed biogenesis mechanism which requires an active endocytic process that may not exist in mature uRBCs (PMCID: [PMC2773486](#), PMID: [3597417](#)). Unlike sEVs, we know uRBCs release medium EVs (mEVs) or microvesicles as shown by many studies. As demonstrated in figure 1b, we could isolate mEVs from uRBCs with detectable protein quantity but this type of EVs were not the subject of our study and therefore not used as negative control. **However, we included additional text in the discussion (page 14 line 17-20) to address the concern raised by the reviewer.***

- Minor comment: figures 2 and 3 don't show statistical differences with the positive controls. Is that normal?

**Reply:** *We didn't add statistics to the positive control condition as we felt this will clutter the figure and it is obvious from the figure that the positive controls have worked as positive controls*

- The cytokine and chemokine results are normalised using the yeo Johnson transformation. Although this method is used in clinical experiments could the

authors explain why it was used on such a small number of patients. Also, this method should be referenced, and the text should explain what the aim of this transformation is and what it is normalised against.

**Reply:** *We used Yeo johnson method to transform the data to conform to normal distribution but not for normalization. This allowed us to use t-test. We modified the text to reflect this and a reference for the method was included as recommended by the reviewer (page 9, line 18-19)*

- How were the 12 or 8 patients used in the different experiments chosen? were there criteria to ensure homogeneity of the populations or were the samples randomised?

**Reply:** *the 12 and 8 PMBC donors consisted of half that grew up in an area of high malaria transmission while the other half grew and reside in an area of minimal malaria transmission. We added additional text to clarify this (page 10, line 15-16 and page 11, line 22-23).*

- Minor comment: y axis on the graphs of figure 2 could be changed to have 2 segments to allow a better representation of the important groups.

**Reply:** *We tried but this approach cuts-off some of the values of the positive controls,*

**Competing Interests:** No competing interest to declare

Reviewer Report 16 November 2020

<https://doi.org/10.21956/wellcomeopenres.17707.r41054>

© 2020 Spadafora C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Carmenza Spadafora**

Center of Cellular and Molecular Biology of Diseases, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), City of Knowledge, Apartado, Panama, Panama

Authors have used a *Plasmodium falciparum* clinical isolate to expand it in the lab and study the immune stimuli that infected erythrocytes from this isolate, or their released small exovesicles, produce on PBMCs from donors.

First, I have two comments on the methodology section. I find it lacks information for others to replicate. Particularly, I note that the description of culture of *P. falciparum* parasites only lists the "ingredients" without specifying their concentrations. If the authors are following the exact recipe of Haynes and Moch or that of Trager and Jensen they should add a reference. If not, then give your own concentrations. The second important petition I have for the group is a better characterization of their sEVs. Even if the methodology of subsequent ultracentrifugations has proceeded well other times, and there is a list of results that the group has obtained from those experiments, it does not mean that in THESE experiments the isolation of EVs was successful. Every time you report a new finding on EVs, you must prove that what you experimented with are indeed EVs. The same holds true for anything that anyone isolates. To expand on this: on the one



hand, the authors, on the referenced publication, show a TEM image of the isolated EVs. In that image there is a number of vesicles of the same size but the morphology inside is different. A minority of them have the doubled – layered membrane that characterizes EVs. There is discussion in the literature about other particles and structures that could have similar sizes. On the other hand, I find it inadequate to give, as a sole proof of the isolation, a silver-stained protein gel showing an enrichment of proteins on a fraction of a given step of the centrifugation methodology that worked in that occasion. It is necessary that some markers of EVs are provided, of the many there are (Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018;7(1):1535750<sup>1</sup>).

Another issue I have with this manuscript is that there is relevant work that has not been cited. There are other general functions reported for EVs and a significant amount of literature focused precisely on the immune response to EVs from *Plasmodium* spp. that the authors should have mentioned in the introduction and then discussed in the conclusions, given that these reports show how PBMCs have been found to respond to plasmodial microparticles, with a direct role in inflammation caused by the disease. Examples are:

- Extracellular vesicles carrying lactate dehydrogenase induce suicide in increased population density of *Plasmodium falciparum* *in vitro*. *Correa et al, 2019*<sup>2</sup>
- Circulating red cell-derived microparticles in human malaria. *Nantakomol et al, 2011*<sup>3</sup>.
- Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. *Couper et al, 2010*<sup>4</sup>
- Augmented plasma microparticles during acute *Plasmodium vivax* infection. *Campos et al. 2010*<sup>5</sup>
- Exosomes from *Plasmodium yoelii*-infected reticulocytes protect mice from lethal infections. *Martin-Jaular et al. 2011*<sup>6</sup>.
- Gillrie MR, Ho M. Dynamic interactions of *Plasmodium* spp. with vascular endothelium. *Tissue Barriers* 2017;5:e1268667<sup>7</sup>.

What can the authors say about the above reports and their results? Do they compare? What are the limitations of using PBMCs *in vitro* and not *in vivo* settings where different surrounding cells would also be releasing their own microparticles and most probably communicating with the infected erythrocytes? Would they foresee a change in the results obtained? How would the immune stimulus change when EVs are signaling a collective suicide? I lack in the discussion precisely that, more of a discussion. For example, what could be the meaning of having the early activation marker CD69 not expressed in monocytes in the presence of infected erythrocytes/sEVs but then having CD25 highly expressed in them when around infected erythrocytes?

Another issue: did not the authors find odd that they could not isolate sEVs from uRBCs given the reports that show how they obtain them, even after filtration with a 0.2 um membrane? (check Correa et al, 2019<sup>2</sup>). Why did they not use silver stain to visualize the proteins in uRBCs as they did with iRBCs or sEVs, but rather chose the much less sensitive Bradford stain for that visualization? Would they have found sEVs from uRBCs had they stained with silver? I believe so.

See Thayer et al, 2019 (Procoagulant activity of red blood cell-derived microvesicles during red cell storage<sup>8</sup>), Kuo et al, 2017 (Red blood cells: a source of extracellular vesicles<sup>9</sup>) or Nowbouossie et al, 2020 article in *Blood* (Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways<sup>10</sup>).

## References

1. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, et al.: Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018; **7** (1): 1535750 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Correa R, Coronado L, Caballero Z, Faral-Tello P, et al.: Extracellular vesicles carrying lactate dehydrogenase induce suicide in increased population density of *Plasmodium falciparum* in vitro. *Scientific Reports*. 2019; **9** (1). [Publisher Full Text](#)
3. Nantakomol D, Dondorp AM, Krudsood S, Udomsangpetch R, et al.: Circulating red cell-derived microparticles in human malaria. *J Infect Dis*. 2011; **203** (5): 700-6 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Couper KN, Barnes T, Hafalla JC, Combes V, et al.: Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. *PLoS Pathog*. 2010; **6** (1): e1000744 [PubMed Abstract](#) | [Publisher Full Text](#)
5. Campos FM, Franklin BS, Teixeira-Carvalho A, Filho AL, et al.: Augmented plasma microparticles during acute *Plasmodium vivax* infection. *Malar J*. 2010; **9**: 327 [PubMed Abstract](#) | [Publisher Full Text](#)
6. Martin-Jaular L, Nakayasu ES, Ferrer M, Almeida IC, et al.: Exosomes from *Plasmodium yoelii*-infected reticulocytes protect mice from lethal infections. *PLoS One*. 2011; **6** (10): e26588 [PubMed Abstract](#) | [Publisher Full Text](#)
7. Gillrie M, Ho M: Dynamic interactions of *Plasmodium* spp. with vascular endothelium. *Tissue Barriers*. 2017; **5** (1). [Publisher Full Text](#)
8. Hashemi Tayer A, Amirizadeh N, Ahmadinejad M, Nikougoftar M, et al.: Procoagulant Activity of Red Blood Cell-Derived Microvesicles during Red Cell Storage. *Transfus Med Hemother*. 2019; **46** (4): 224-230 [PubMed Abstract](#) | [Publisher Full Text](#)
9. Kuo WP, Tigges JC, Toxavidis V, Ghiran I: Red Blood Cells: A Source of Extracellular Vesicles. *Methods Mol Biol*. 2017; **1660**: 15-22 [PubMed Abstract](#) | [Publisher Full Text](#)
10. Noubouossie D, Henderson M, Mooberry M, Ilich A, et al.: Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. *Blood*. 2020; **135** (10): 755-765 [Publisher Full Text](#)

**Is the work clearly and accurately presented and does it cite the current literature?**

Partly

**Is the study design appropriate and is the work technically sound?**

Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Parasitology, Plasmodium falciparum Exovesicles, Drug Discovery, Biophysics of Plasmodium falciparum

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 18 Mar 2021

**Abdirahman Abdi**, KEMRI-Wellcome Trust, CGMRC, Kilifi, Kenya

We are grateful to the reviewer's time and useful comments/suggestions. Below we provide point by point response to the reviewers comments.

Authors have used a *Plasmodium falciparum* clinical isolate to expand it in the lab and study the immune stimuli that infected erythrocytes from this isolate, or their released small exovesicles, produce on PBMCs from donors.

First, I have two comments on the methodology section. I find it lacks information for others to replicate. Particularly, I note that the description of culture of *P. falciparum* parasites only lists the "ingredients" without specifying their concentrations. If the authors are following the exact recipe of Haynes and Moch or that of Trager and Jensen they should add a reference. If not, then give your own concentrations.

**Reply:** *We have now included the concentration of the ingredient*

The second important petition I have for the group is a better characterization of their sEVs. Even if the methodology of subsequent ultracentrifugations has proceeded well other times, and there is a list of results that the group has obtained from those experiments, it does not mean that in THESE experiments the isolation of EVs was successful. Every time you report a new finding on EVs, you must prove that what you experimented with are indeed EVs. The same holds true for anything that anyone isolates. To expand on this: on the one hand, the authors, on the referenced publication, show a TEM image of the isolated EVs. In that image there is a number of vesicles of the same size but the morphology inside is different. A minority of them have the doubled - layered membrane that characterizes EVs. There is discussion in the literature about other particles and structures that could have similar sizes. On the other hand, I find it inadequate to give, as a sole proof of the isolation, a silver-stained protein gel showing an enrichment of proteins on a fraction of a given step of the centrifugation methodology that worked in that occasion. It is necessary that some markers of EVs are provided, of the many there are (Théry C, Witwer KW, Aikawa E, et al.

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018;7(1):1535750<sup>1</sup>).

**Reply:** *First, we would like to state, to our knowledge, that Plasmodium falciparum EVs do not have well established markers that can be targeted with western blot analysis however, although we have used an established method for isolating sEVs and which we previously used to successfully isolate EVs whose size and density match that of sEVs, in this study we have not provided evidence of successful EV isolation as we had no access to the necessary equipment. We have admitted this as a limitation of the study under the discussion section (page 14, line 21-25)*

Another issue I have with this manuscript is that there is relevant work that has not been cited. There are other general functions reported for EVs and a significant amount of literature focused precisely on the immune response to EVs from Plasmodium spp. that the authors should have mentioned in the introduction and then discussed in the conclusions, given that these reports show how PBMCs have been found to respond to plasmodial microparticles, with a direct role in inflammation caused by the disease. Examples are:

- Extracellular vesicles carrying lactate dehydrogenase induce suicide in increased population
- Circulating red cell-derived microparticles in human malaria. *Nantakomol et al, 2011*<sup>3</sup>.
- Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. *Couper et al, 2010*<sup>4</sup>
- Augmented plasma microparticles during acute Plasmodium vivax infection. *Campos et al. 2010*<sup>5</sup>
- Exosomes from Plasmodium yoelii-infected reticulocytes protect mice from lethal infections. *Martin-Jaular et al. 2011*<sup>6</sup>.
- Gillrie MR, Ho M. Dynamic interactions of Plasmodium spp. with vascular endothelium. *Tissue Barriers* 2017;5:e1268667<sup>7</sup>.

What can the authors say about the above reports and their results? Do they compare? What are the limitations of using PBMCs *in vitro* and not *in vivo* settings where different surrounding cells would also be releasing their own microparticles and most probably communicating with the infected erythrocytes? Would they foresee a change in the results obtained? How would the immune stimulus change when EVs are signaling a collective suicide? I lack in the discussion precisely that, more of a discussion. For example, what could be the meaning of having the early activation marker CD69 not expressed in monocytes in the presence of infected erythrocytes/sEVs but then having CD25 highly expressed in them when around infected erythrocytes?

**Reply:** *We considered the reviewer's suggestion and we have now cited most of the papers recommended by the reviewer especially those relevant to host: parasite interaction. We also added some text in the discussion (page 14, line 34-36 to) to note the complexity of interaction that may happen in vivo as compared to in vitro. With regards to "the meaning of having the early activation marker CD69 not expressed in monocytes in the presence of infected erythrocytes/sEVs but then having CD25 highly expressed in them when around infected erythrocytes?", our interpretation is that, by the time we assessed the expression of the activation markers, which is after 18 hours of stimulation, CD69 expression has already declined while CD25*

*is on the increase/peaked.*

Another issue: did not the authors find odd that they could not isolate sEVs from uRBCs given the reports that show how they obtain them, even after filtration with a 0.2 um membrane? (check Correa et al, 2019<sup>2</sup>). Why did they not use silver stain to visualize the proteins in uRBCs as they did with iRBCs or sEVs, but rather chose the much less sensitive Bradford stain for that visualization? Would they have found sEVs from uRBCs had they stained with silver? I believe so.

- **Reply:** *We appreciate the reviewer's suggestion of using silver staining to prove/disapprove presence of sEVs but we believe this would not have been useful to our experiments as we needed to obtain sEVs containing a quantifiable amount of protein which can be used as control for the sEVs isolated from iRBCs to stimulate PBMCs from 20 donors. We spent a lot of time to see if we can isolate sEVs from uRBCs but we were not successful in isolating enough to support PBMC stimulation experiments for 20 PBMC donors. Even Correa et al. Parasites & Vectors (2017) 10:215 admitted that they struggled to isolate enough sEVs from uRBCs. Again, our finding makes biological sense considering the proposed mechanism for sEVs biogenesis which requires active endocytosis process which may not exist in mature RBCs as suggested by several studies(PMCID: [PMC2773486](#), PMID: [3597417](#))*

See Thayer et al, 2019 (Procoagulant activity of red blood cell-derived microvesicles during red cell storage<sup>8</sup>), Kuo et al, 2017 (Red blood cells: a source of extracellular vesicles<sup>9</sup>) or Nowbouossie et al, 2020 article in Blood (Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways<sup>10</sup>).

**Reply:** *As demonstrated in figure 1b, we also successfully isolated mEVs (microvesicles) from uRBCs and these are the type of EVs discussed in the papers referenced by the reviewer. What we could not isolate using our method is the sEVs(exosomes) from uRBCs and we believe our finding makes sense given the proposed biogenesis mechanism of sEVs that involves endocytic pathway which mature RBCs might have lost(PMCID: [PMC2773486](#), PMID: [3597417](#))*

**Competing Interests:** No competing interest to declare

Reviewer Report 10 November 2020

<https://doi.org/10.21956/wellcomeopenres.17707.r41182>

© 2020 Mbagwu S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✓ Smart Ikechukwu Mbagwu 

Anatomy Unit, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Germany

I have read the article titled Impact of *Plasmodium falciparum* small-sized extracellular vesicles on host peripheral blood mononuclear cells. The key findings of this work is that there is differential induction of immune response on peripheral blood mononuclear cells by extracellular vesicles derived from malaria infected red blood cells and the plasmodium falciparum infected red blood cells. This differential immune response induced is exerted by the Th17 and Th1 actions which is yet to be fully characterized. In addition the paper details the decline in the capacity of the extracellular vesicles to activate monocytes.

The introduction of the paper was well written with relevant references cited. However, the opening sentence seems to be missing some texts. The authors need to check this out. The methods used were well described but since the aim of the work was to compare the functional impact of *PfsEVs* and the autochthonous *PfiRBCs* of a clinical isolate adapted to short-term culture (<70 cycles) on human peripheral blood mononuclear cells (PBMC). Were there no other methods that could have been employed in the study eg rt-qPCR? I am not sure it is clear what the authors meant by "probably enriched".

The results are clear but it could be more interesting if the authors could demonstrate why infected RBCs release more extracellular vesicles.

The discussion provides a summary of the findings of the study. However, the authors did not provide a clarity on why the difference in the induction of immune response as shown by the level of expression of the activation markers was observed and a justification for the observation. The significance of their observation is not clearly detailed and how this can be provide an insight to an in vivo condition. Do the authors think that different isolates of the *Plasmodium falciparum* could give a different observation from their study findings?

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Malaria, Extracellular vesicles, Brain endothelial cells, Microglia

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 18 Mar 2021

**Abdirahman Abdi**, KEMRI-Wellcome Trust, CGMRC, Kilifi, Kenya

We are grateful to the reviewer for positive comments. Below we provide point by point response to reviewers comments.

I have read the article titled Impact of *Plasmodium falciparum* small-sized extracellular vesicles on host peripheral blood mononuclear cells. The key findings of this work is that there is differential induction of immune response on peripheral blood mononuclear cells by extracellular vesicles derived from malaria infected red blood cells and the plasmodium falciparum infected red blood cells. This differential immune response induced is exerted by the Th17 and Th1 actions which is yet to be fully characterized. In addition, the paper details the decline in the capacity of the extracellular vesicles to activate monocytes.

The introduction of the paper was well written with relevant references cited. However, the opening sentence seems to be missing some texts. The authors need to check this out.

**Reply:** *We are grateful to the reviewer for the positive comments. We slightly modified the opening sentence.*

The methods used were well described but since the aim of the work was to compare the functional impact of *PfsEVs* and the autochthonous *PfiRBCs* of a clinical isolate adapted to short-term culture (<70 cycles) on human peripheral blood mononuclear cells (PBMC). Were there no other methods that could have been employed in the study eg rt-qPCR? I am not sure it is clear what the authors meant by "probably enriched".

**Reply:** *About use of RT-qPCR, we agree that RT-qPCR could be an alternative or complementary method of analyzing the impact of *PfsEVs* on PBMCs, however, in this study we opted to analyze at the protein level by targeting protein markers known to be expressed upon activation of PBMCs.*

The results are clear, but it could be more interesting if the authors could demonstrate why infected RBCs release more extracellular vesicles.

**Reply:** *We think the increased amount proteins detected in mEVs from infected RBCs could be due to the parasite-derived proteins packaged into the mEVs and the infection might also increase the rate of release of mEVs from infected RBCs as compared to uRBCs. We added additional text to clarify this (page 10, line 4-6).*

The discussion provides a summary of the findings of the study. However, the authors did not provide a clarity on why the difference in the induction of immune response as shown by the level of expression of the activation markers was observed and a justification for the observation. The significance of their observation is not clearly detailed and how this can be provide an insight to an in vivo condition. Do the authors think that different isolates of the *Plasmodium falciparum* could give a different observation from their study findings?

**Reply:** *We appreciate the reviewer's positive comments. We agree with the reviewer that although we attempted to discuss our result in the context of what is known, we avoided speculating the mechanism behind the difference observed with PfsEVs and PfiRBCs as we currently don't understand but we shall explore it in future studies. We also preferred to keep the discussion short.*

**Competing Interests:** no competing interest to declare

---